Log in to search using one of your social media accounts:

 

GSK wins $235 million from Teva in Coreg patent trial
(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. (Source: Reuters: Health)
Source: Reuters: Health - June 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Beta blocker shows cancer-fighting properties
A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer. The research could lead better ways to protect our skin from the sun. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 24, 2017 Category: Science Source Type: news

Beta blocker shows cancer-fighting properties
(Experimental Biology 2017) A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer. The research could lead better ways to protect our skin from the sun. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2017 Category: Cancer & Oncology Source Type: news

Coreg CR (Carvedilol Phosphate Extended-Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 25, 2016 Category: Drugs & Pharmacology Source Type: news

Coreg (Carvedilol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 25, 2016 Category: Drugs & Pharmacology Source Type: news

Carvedilol Delays Progression of Small Esophageal VaricesCarvedilol Delays Progression of Small Esophageal Varices
Treatment with carvedilol helps delay progression of small esophageal varices in patients with cirrhosis, suggest a trial conducted in India. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Joshua’s story: Advances in medical management of pediatric heart failure
In recent years, the Boston Children’s Hospital Heart Failure team has made significant strides in slowing the progress of heart failure in children. In some cases, disease progression has been slowed enough for the patient to be taken off of the heart transplant list for being “too well.” The following is part four of a four-part series featuring  Boston Children’s Heart Center patients who were once listed for transplant but were removed thanks to successful medical management of his heart disease. Surgery before birth Joshua Brennan, now 12, was diagnosed with complex congenital heart d...
Source: Thrive, Children's Hospital Boston - December 7, 2015 Category: Pediatrics Authors: Erin Horan Tags: Our Patients’ Stories congenital heart disease Dr. Tajinder Singh Dr. Wayne Tworetsky heart failure Heart transplant program Source Type: news

Kalev’s story: Advances in medical management of pediatric heart failure
In recent years, the Boston Children’s Hospital Heart Failure team has made significant strides in slowing the progress of heart failure in children. In some cases, disease progression has been slowed enough for the patient to be taken off of the heart transplant list for being “too well.” The following is part three of a four-part series featuring Heart Center patients who were once listed for transplant but were removed thanks to successful medical management of his or her heart disease. Searching for answers Thirty weeks into her second pregnancy, Katie Rosenthal just felt like something was wrong. She...
Source: Thrive, Children's Hospital Boston - November 30, 2015 Category: Pediatrics Authors: Erin Horan Tags: Our patients’ stories congenital heart disease Dr. Leslie Smoot Dr. Pedro del Nido Dr. Sitiram Emani Dr. Wayne Tworetsky heart failure heart transplant Heart transplant program Source Type: news

carvedilol (Coreg, Coreg CR)
Title: carvedilol (Coreg, Coreg CR)Category: MedicationsCreated: 1/16/2000 1:11:00 PMLast Editorial Review: 8/7/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 7, 2014 Category: Drugs & Pharmacology Source Type: news

carvedilol (Coreg, Coreg CR)
Title: carvedilol (Coreg, Coreg CR)Category: MedicationsCreated: 1/16/2000 1:11:00 PMLast Editorial Review: 8/7/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 7, 2014 Category: Cardiology Source Type: news

Digoxin toxicity: check the magnesium level!
3 out of 5 stars Digoxin Toxicity with Normal Digoxin and Serum Potassium Levels: Beware of Magnesium, the Hidden Malefactor. Rao MPR et al. J Emerg Med 2013 May 16 [Epub ahead of print] Abstract This case report from Oman describes at 66-year-old woman (inexplicably described as “elderly”) who presented to hospital with one day of nausea, vomiting, abdominal distress, and palpitations. Her medications included furosemide, spironolactone, digoxin, carvedilol, lisinopril, metformin, and calcium. Initial EKGs showed evidence of junctional tachycardia and digoxin effect. The treating physicians initially cons...
Source: The Poison Review - May 23, 2013 Category: Toxicology Authors: Leon Tags: Medical digitalis digoxin toxicity hypomagnesemia magnesium potassium Source Type: news

Preventing Heart Damage From Chemotherapy: OVERCOME TrialPreventing Heart Damage From Chemotherapy: OVERCOME Trial
A pilot study shows that the combination of enalapril plus carvedilol prevented left ventricular damage in cancer patients undergoing intensive chemotherapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Carvedilol superior to metoprolol in MADIT-CRT analysis
The benefit of carvedilol over metoprolol was more pronounced in the subgroup of patients with a CRT-D, where carvedilol was associated with a significant 39% reduction in the risk of hospitalization for HF or death, and in those with left bundle branch block. (Source: theHeart.org)
Source: theHeart.org - April 2, 2013 Category: Cardiology Source Type: news

Carvedilol Beats Metoprolol in Some HF Patients (CME/CE)
(MedPage Today) -- Patients with mild heart failure and an implanted CRT-D device to regulate heart rhythm appear to do better with the beta-blocker carvedilol than with metoprolol, a subanalysis of MADIT-CRT suggested. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 2, 2013 Category: Cardiology Source Type: news

RCT: Metoprolol vs carvedilol, or carvedilol plus N-acetylcysteine on post-operative atrial fibrillation
Source: Eur Heart J Area: News The aim of this study was to evaluate the efficacy of metoprolol, carvedilol, and carvedilol plus NAC on the prevention of post-operative atrial fibrillation (POAF).   Three hundred and eleven patients undergoing cardiac surgery were randomised to metoprolol, carvedilol, or carvedilol plus NAC. The incidence of POAF was statistically lower in the carvedilol plus NAC group compared with the metoprolol group (P
Source: NeLM - Cardiovascular Medicine - February 22, 2013 Category: Cardiology Source Type: news

A Carvedilol Revolution: Hypertension to Heart Failure and Beyond
It appears that the attractiveness of beta-blockers is waning for patients with heart failure and also for those with acute MI. Carvedilol is becoming a preferred agent. (Source: Consultant Live)
Source: Consultant Live - February 8, 2013 Category: Primary Care Source Type: news

Meta-Analysis: Beta-Blockers and outcome in heart failure and atrial fibrillation
Source: J Am Coll Cardiol Heart Failure Area: News Although beta-blockers are widely used for the treatment of heart failure (HF), little is known about their efficacy in patients with co-existing atrial fibrillation (AF).   To investigate, researchers conducted a meta-analysis of placebo-controlled, randomised beta-blocker therapy in patients with AF at baseline and HF with reduced systolic left ventricular ejection fraction (LVEF)
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news

Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Source: BMJ Area: News Beta blockers have been shown in randomised trials to prolong survival, prevent arrhythmia, improve symptoms of heart failure and left ventricular ejection fraction, and control ventricular rate, especially in patients with chronic heart failure. However, controversy exists as to the optimal selection of a particular agent for management of heart failure, as they differ in their selectivity for adrenergic receptors and their effects on the peripheral circulation.   This systematic review and network meta-analysis was conducted of efficacy of different beta- blockers in heart failure to clar...
Source: NeLM - Cardiovascular Medicine - January 17, 2013 Category: Cardiology Source Type: news

All Beta-Blockers Not Created Equal (CME/CE)
(MedPage Today) -- Compared with other beta-blockers, carvedilol may lead to better outcomes in patients with heart failure and acute myocardial infarction, a meta-analysis showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - January 11, 2013 Category: Consumer Health News Source Type: news